Biogen/$BIIB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Biogen
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
- Ticker
- $BIIB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 7,500
- Headquarters
- Cambridge, United States
- Website
- www.biogen.com
Biogen Metrics
BasicAdvanced
$37B
108.47
$2.34
0.09
-
Price and volume
Market cap
$37B
Beta
0.09
52-week high
$261.00
52-week low
$158.05
Average daily volume
1.3M
Financial strength
Current ratio
1.946
Quick ratio
0.946
Long term debt to equity
0.391
Total debt to equity
0.412
Interest coverage (TTM)
7.94%
Profitability
EBITDA (TTM)
3,302.1
Gross margin (TTM)
75.77%
Net profit margin (TTM)
3.37%
Operating margin (TTM)
23.50%
Effective tax rate (TTM)
21.93%
Revenue per employee (TTM)
$1,370,000
Management effectiveness
Return on assets (TTM)
4.94%
Return on equity (TTM)
1.87%
Valuation
Price to earnings (TTM)
108.468
Price to revenue (TTM)
3.625
Price to book
1.98
Price to tangible book (TTM)
-25.82
Price to free cash flow (TTM)
22.703
Free cash flow yield (TTM)
4.40%
Free cash flow per share (TTM)
11.162
Growth
Revenue change (TTM)
2.30%
Earnings per share change (TTM)
-78.71%
3-year revenue growth (CAGR)
1.00%
10-year revenue growth (CAGR)
-1.03%
3-year earnings per share growth (CAGR)
-38.52%
10-year earnings per share growth (CAGR)
-18.32%
What the Analysts think about Biogen
Analyst ratings (Buy, Hold, Sell) for Biogen stock.
Analyst projections of the future price of Biogen stock.
Bulls say / Bears say
Biogen’s growth portfolio rose 24% year on year to $1.06 billion in the second quarter, helping lift total revenue 3%. The company now expects full-year revenue to grow by a mid-single-digit percentage, reversing its earlier forecast for a decline. (SEC)
The FDA approved at-home initiation of Leqembi, giving patients an alternative to starting treatment by clinic infusion. Easier administration could support uptake and help the drug stand out from its infused competitor. (Reuters)
Biogen expects five late-stage trial readouts over the next four quarters, including studies in lupus, kidney disease and Dravet syndrome. Positive results could add new growth drivers beyond its marketed portfolio. (SEC)
Multiple sclerosis product revenue fell 13% year on year to $963 million in the second quarter, as generic and other competitive pressure continued to weigh on the legacy franchise. (SEC)
Biogen’s experimental Alzheimer’s drug diranersen missed its Phase 2 primary goal, and the company did not disclose the size of the observed benefit. Advancing it to late-stage trials therefore carries meaningful efficacy risk. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
Biogen Financial Performance
Revenues and expenses
Biogen Earnings Performance
Company profitability
Upcoming events
No upcoming events
Biogen News
AllArticlesVideos
Funds containing Biogen
AllUSDEURGBP
Fund name | Fund size | $BIIB weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 2.36% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 2.36% |
iShares Healthcare Innovation£DRDR | $1.6B | 1.48% |
iShares Healthcare Innovation$HEAL | $1.6B | 1.48% |
iShares Healthcare Innovation€2B78 | $1.6B | 1.48% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.